EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring Raloxifene‐Based Metallodrugs: A Versatile Vector Combined with Platinum(II), Palladium(II) and Nickel(II) Dichlorides and Carborates against Triple‐Negative Breast Cancer

Aleksandr Kazimir iD, Tom Götze iD, Peter Lönnecke iD, Blagoje Murganić iD, Sanja Mijatović iD, Danijela Maksimović-Ivanić iD, Evamarie Hey-Hawkins iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Aleksandr Kazimir und 6 weiteren Autor:innen. Beteiligte Einrichtung: new address, Institute for Drug Discovery, Leipzig University, Leipzig, Brüderstraße 34, 04103, Germany. Hauptthemen laut MEDLINE: Palladium, Nickel, Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation of the Republic of Serbia, DAAD, Research Grants Bi-national.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) poses challenges in therapy due to the absence of target expression such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Frequently, the treatment of TNBC involves the combination of several therapeutics. However, an enhanced therapeutic effect can be also achieved within a single molecule. The efficacy of raloxifene can be improved by designing a raloxifene‐based hybrid drug bearing a 2,2’‐bipyridine moiety ( 2 ). Integration of platinum(II), palladium(II), and nickel(II) complexes into this structure dramatically changed the cytotoxicity. The platinum(II) dichloride complex 3 did not demonstrate any activity, while palladium(II) and nickel(II) dichloride complexes 4 and 5 exhibited various cytotoxic behavior towards different types of hormone‐receptor positive (HR+) cancer and TNBC cell lines. The replacement of the two chlorido ligands in 3 – 5 with a dicarbollide (carborate) ion [C 2 B 9 H 11 ] 2− resulted in reduced activity of compounds 6 , 7 , and 8 . However, the palladacarborane complex 7 demonstrated higher selectivity towards TNBC. Furthermore, the mechanism of action was shifted from cytotoxic to explicitly cytostatic with detectable proliferation arrest and accelerated aging, characterized by senescence‐associated phenotype of TNBC cells. This study provides valuable insights into the development of hybrid therapeutics against TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PalladiumNickelTriple Negative Breast NeoplasmsAntineoplastic AgentsPlatinumCoordination ComplexesCell ProliferationRaloxifene HydrochlorideDrug Screening Assays, AntitumorHumansCell Line, TumorStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugFemale

Stichwörter der Autor:innen

TNBCmetallacarboranemetallodrugsnickelpalladiumplatinumraloxifenesenescence

Substanzen

PalladiumNickelAntineoplastic AgentsPlatinumCoordination ComplexesRaloxifene Hydrochloride

Autor:innen und Institutionen

  • new address, Institute for Drug Discovery, Leipzig University, Leipzig, Brüderstraße 34, 04103, Germany.
  • Faculty of Chemistry and Mineralogy, Leipzig University, Johannisallee 29, Leipzig, 04103, Germany.
  • Institute of Nuclear Sciences "Vinča", University of Belgrade, 12-14 Mike Petrovića Street, Belgrade, 11351, Serbia.
  • Department of Immunology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, Belgrade University, Bul. despota Stefana 142, Belgrade, 11060, Serbia.

ORCID-Profile: Aleksandr Kazimir, Tom Götze, Peter Lönnecke, Blagoje Murganić, Sanja Mijatović, Danijela Maksimović-Ivanić, Evamarie Hey-Hawkins

Förderung

  • Ministry of Science, Technological Development and Innovation of the Republic of Serbia
  • DAAD
  • Research Grants Bi-national
  • Projekt DEAL

Zitieren

APA

Kazimir, A., Götze, T., Lönnecke, P., Murganić, B., Mijatović, S., Maksimović-Ivanić, D., & Hey-Hawkins, E. (2024). Exploring Raloxifene‐Based Metallodrugs: A Versatile Vector Combined with Platinum(II), Palladium(II) and Nickel(II) Dichlorides and Carborates against Triple‐Negative Breast Cancer. ChemMedChem. https://doi.org/10.1002/cmdc.202400006

Vancouver

Kazimir A, Götze T, Lönnecke P, Murganić B, Mijatović S, Maksimović-Ivanić D, et al. Exploring Raloxifene‐Based Metallodrugs: A Versatile Vector Combined with Platinum(II), Palladium(II) and Nickel(II) Dichlorides and Carborates against Triple‐Negative Breast Cancer. ChemMedChem. 2024. doi:10.1002/cmdc.202400006

BibTeX
@article{Kazimir2024,
  author = {Kazimir, Aleksandr and Götze, Tom and Lönnecke, Peter and Murganić, Blagoje and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie},
  title = {Exploring Raloxifene‐Based Metallodrugs: A Versatile Vector Combined with Platinum(II), Palladium(II) and Nickel(II) Dichlorides and Carborates against Triple‐Negative Breast Cancer},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400006}
}
Kostenlos starten →